Affinage

CSNK2B

Casein kinase II subunit beta · UniProt P67870

Round 2 corrected
Length
215 aa
Mass
24.9 kDa
Annotated
2026-04-28
66 papers in source corpus 19 papers cited in narrative 19 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CSNK2B encodes CK2β, the regulatory subunit of casein kinase 2, which homodimerizes via a conserved zinc-finger domain to bridge two CK2α catalytic subunits into a heterotetrameric holoenzyme; this architecture stabilizes CK2α and modulates its substrate specificity, as exemplified by the FACT-CK2 complex that redirects kinase activity from casein to p53-Ser392 (PMID:11574463, PMID:11239457). Beyond canonical kinase scaffolding, CK2β participates in the PRC1-AUTS2 epigenetic activation complex in the CNS, enhances IRF1 chromatin binding to drive antiviral gene expression, and engages DVL3/β-catenin to support canonical Wnt signaling, while its protein stability is controlled by TNFAIP1-Cul3-mediated ubiquitination and RACK1-dependent stabilization that gate NF-κB pathway output (PMID:25519132, PMID:37094077, PMID:35571680, PMID:31901862, PMID:38398158). Haploinsufficiency of CSNK2B reduces holoenzyme formation and kinase activity, impairs neural stem cell differentiation and synaptic transmission, and causes Poirier-Bienvenu neurodevelopmental syndrome characterized by seizures and intellectual disability (PMID:36833176, PMID:29483533).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 1994 Medium

    Identification of a conserved zinc-finger motif in CK2β-family subunits and demonstration of functional interaction with both catalytic subunits established the structural basis for CK2β's role as a regulatory scaffold.

    Evidence Gene cloning of yeast CKB2, sequence analysis of CPX3C-X22-CPXC motif, genetic epistasis via double-mutant synthetic phenotypes in S. cerevisiae

    PMID:8027080

    Open questions at the time
    • Single-lab yeast study; mammalian conservation of functional interactions not yet tested
    • No biochemical reconstitution of catalytic subunit–β interaction
  2. 1995 High

    Genetic disruption of the yeast CK2β ortholog resolved whether the regulatory subunit was essential, revealing it is dispensable for viability but required for ion homeostasis, defining CK2β as a modulator rather than an obligate activator.

    Evidence Gene disruption of CKB1 in S. cerevisiae, salt sensitivity growth assays

    PMID:7737972

    Open questions at the time
    • Yeast-specific phenotype; mammalian essentiality remained unaddressed
    • Mechanism of ion homeostasis involvement unclear
  3. 2001 High

    The crystal structure of the CK2 holoenzyme answered the central question of how CK2β organizes the tetramer, revealing that CK2β homodimerizes and each catalytic subunit contacts both β chains via an extended C-terminal tail, with no direct α–α contact.

    Evidence X-ray crystallography of truncated human CK2 holoenzyme at 3.1 Å resolution

    PMID:11574463

    Open questions at the time
    • Structure used truncated constructs; full-length holoenzyme flexibility unknown
    • Dynamic regulation of assembly not captured
  4. 2001 High

    Demonstration that FACT recruits CK2 to phosphorylate p53-Ser392 upon UV irradiation, switching CK2 substrate specificity away from casein, established that CK2β participates in substrate-selective adaptor complexes beyond the canonical holoenzyme; concurrently, CK2 phosphorylation of Bid was shown to render it caspase-8-resistant, linking CK2β-containing complexes to apoptosis regulation.

    Evidence Biochemical purification of FACT-CK2 complex, in vitro kinase and substrate specificity assays, Bid mutagenesis, Fas apoptosis readouts

    PMID:11239457 PMID:11583622

    Open questions at the time
    • In vivo relevance of Bid phosphorylation by CK2 not confirmed genetically
    • Whether CK2β directly contacts FACT subunits or is a passive scaffold unknown
  5. 2014 High

    Discovery that CK2 (including CK2β) is a component of the PRC1-AUTS2 complex that converts Polycomb from a repressor to a transcriptional activator in the CNS expanded CK2β's role into chromatin regulation and neurodevelopmental gene expression.

    Evidence Biochemical purification of PRC1-AUTS2 complex, ChIP-seq, conditional mouse CNS knockout

    PMID:25519132

    Open questions at the time
    • Direct CK2β phosphorylation targets within the PRC1-AUTS2 complex not identified
    • Whether kinase activity or scaffolding function of CK2β is required not dissected
  6. 2018 Medium

    Loss-of-function studies in neural stem cells demonstrated that CSNK2B is required for proper neuronal differentiation and synaptic transmission, establishing a cell-autonomous neuronal requirement prior to the identification of human disease mutations.

    Evidence shRNA knockdown in neural stem cells, proliferation/differentiation assays, neuronal morphology and synaptic transmission measurements

    PMID:29483533

    Open questions at the time
    • shRNA knockdown may have off-target effects; genetic knockout not performed
    • Specific CK2 substrates mediating the differentiation defect not identified
  7. 2020 High

    Identification of TNFAIP1 as a factor that promotes Cul3-mediated ubiquitination and degradation of CK2β, attenuating NF-κB signaling, revealed a regulated protein turnover mechanism for controlling CK2β levels and downstream pathway activity.

    Evidence LC-MS/MS, reciprocal Co-IP, ubiquitination and Western blot assays, dual-luciferase reporter, in vivo rescue experiments in hepatocellular carcinoma

    PMID:31901862

    Open questions at the time
    • Specific Cul3 adaptor (BTB-domain protein) bridging TNFAIP1 to Cul3 not identified
    • Whether this degradation mechanism operates in non-cancer contexts unknown
  8. 2022 High

    Functional characterization of Poirier-Bienvenu syndrome Asp32 variants resolved how specific missense mutations disrupt CK2β: impaired interaction with DVL3/β-catenin, loss of β-catenin phosphorylation and nuclear accumulation, and global loss of phosphorylation at hundreds of putative CK2 substrates enriched in Wnt pathway components.

    Evidence Patient-derived lymphoblastoid cell lines, Co-IP, whole-transcriptome and phosphoproteome mass spectrometry, immunofluorescence

    PMID:35571680

    Open questions at the time
    • Whether Wnt dysregulation is the primary driver of neurological symptoms versus other affected pathways not established
    • Rescue experiments not performed
  9. 2023 High

    Multiple studies converged on new CK2β functions: direct interaction with IRF1 broadly enhances antiviral chromatin binding, positioning CK2β as an innate immune cofactor; haploinsufficiency was confirmed as the pathomechanism of Poirier-Bienvenu syndrome through mRNA/protein instability and reduced holoenzyme formation; and CSNK2B was shown essential for erythropoiesis downstream of the lncRNA HIKER.

    Evidence CUT&RUN genome-wide chromatin profiling and antiviral assays (IRF1); patient-derived cell mRNA/protein stability and kinase assays (Poirier-Bienvenu); lncRNA knockdown/rescue, CK2 inhibitor, zebrafish morpholino (erythropoiesis)

    PMID:36833176 PMID:37022795 PMID:37094077

    Open questions at the time
    • IRF1–CK2β interaction surface and whether kinase activity is required for chromatin targeting not mapped
    • Whether erythropoiesis defects are CK2α-activity-dependent or scaffolding-dependent unclear
    • Poirier-Bienvenu variant spectrum and genotype-phenotype correlation incomplete
  10. 2024 Medium

    RACK1 was identified as a stabilizer of CK2β that inhibits its ubiquitination, enabling NF-κB activation and CDK4/cyclin D3 transcription to drive cell cycle progression in meningioma, establishing a second layer of post-translational CK2β regulation opposing the TNFAIP1-Cul3 axis.

    Evidence Co-IP/mass spectrometry, RNAi, transcriptome sequencing, in vivo nude mouse xenografts

    PMID:38398158

    Open questions at the time
    • Single-lab study; RACK1–CK2β interaction not independently replicated
    • Whether RACK1 competes with TNFAIP1 for the same CK2β surface not tested
  11. 2025 Medium

    Variant-class-specific mechanisms were delineated: zinc-finger domain missense variants destabilize CK2β and impair homodimerization without affecting CK2α binding, while Asp32/Arg86 variants preserve stability but disrupt downstream signaling, establishing that distinct pathogenic variants converge on disease through different molecular defects.

    Evidence Co-IP for homodimerization and CK2α binding, proteasome/lysosome inhibitor assays, immunofluorescence localization of CK2β variants

    PMID:40317201

    Open questions at the time
    • Not independently replicated; patient-level phenotypic correlation with variant class not established
    • Whether altered localization of zinc-finger variants has functional signaling consequences not tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include: (1) the full spectrum of CK2β-dependent substrates altered in Poirier-Bienvenu syndrome neural tissue, (2) whether CK2β's scaffolding versus kinase-enabling functions are separable in vivo, and (3) whether gene replacement therapy can translate from murine models to human disease.
  • No separation-of-function alleles distinguishing scaffold from kinase-enabling roles
  • In vivo phosphoproteomics in neural tissue of haploinsufficient models not performed
  • AAV gene therapy data remain in preprint

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 5 GO:0060090 molecular adaptor activity 4
Localization
GO:0005634 nucleus 3 GO:0005829 cytosol 2
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-1266738 Developmental Biology 2 R-HSA-1640170 Cell Cycle 2 R-HSA-168256 Immune System 1 R-HSA-4839726 Chromatin organization 1 R-HSA-5357801 Programmed Cell Death 1
Partners
CSNK2A1CTNNB1DVL3IRF1RACK1SSRP1SUPT16HTNFAIP1
Complex memberships
CK2 holoenzyme (α2β2 heterotetramer)FACT-CK2 complexPRC1-AUTS2 complex

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 Crystal structure of the human CK2 holoenzyme at 3.1 Å resolution revealed that the two regulatory (CK2β/CSNK2B) subunits form a stable dimer that links the two catalytic subunits, which make no direct contact with one another. Each catalytic subunit interacts with both regulatory chains predominantly via an extended C-terminal tail of CK2β. X-ray crystallography of truncated CK2 holoenzyme The EMBO journal High 11574463
2001 FACT (hSpt16/SSRP1) associates with CK2 (containing the CK2β subunit) to form a UV-activated kinase complex that selectively phosphorylates p53 at Ser-392; FACT alters CK2 substrate specificity within the complex, switching preference away from casein toward p53, and this phosphorylation enhances p53 activity. Biochemical purification, in vitro kinase assay, functional p53 activity assay Molecular cell High 11239457
2001 Bid is phosphorylated by casein kinase II (CKII, which contains CSNK2B as its regulatory subunit); phosphorylated Bid is insensitive to caspase-8 cleavage in vitro, and inhibition of CKII accelerated Fas-mediated apoptosis and Bid cleavage, whereas kinase hyperactivity delayed apoptosis. In vitro kinase assay, site-specific mutagenesis, caspase-8 cleavage assay, Fas apoptosis assay Molecular cell High 11583622
1995 Cloning and disruption of CKB1 (the yeast ortholog of CSNK2B) demonstrated that the regulatory β subunit of CK2 is dispensable for viability, mating, and sporulation in S. cerevisiae, but strains lacking CKB1 (alone or combined with CKB2) are sensitive to NaCl and LiCl, indicating a role for the regulatory subunit in ion homeostasis. Gene disruption, salt sensitivity growth assays, phenotypic analysis of haploid/diploid yeast mutants The Journal of biological chemistry High 7737972
1994 Cloning of CKB2 (yeast β'-subunit paralog) revealed that the β'-subunit shares a conserved CPX3C-X22-CPXC metal-binding (zinc finger) motif with other CK2β subunits. Double disruption of CKB2 with either catalytic subunit gene causes synthetic slow growth and flocculation, demonstrating that CKB2 interacts functionally with both catalytic subunits in vivo. Gene cloning, sequence analysis, genetic epistasis via double-mutant synthetic phenotype The Journal of biological chemistry Medium 8027080
1996 CSNK2B was mapped to the class III region of the human major histocompatibility complex on chromosome 6, approximately 220 kb from known flanking genes, establishing its genomic locus. cDNA isolation, Northern blot, exon trapping, genomic sequencing Genomics Medium 8812450
2013 Chimeric transcripts between CSNK2B and the downstream Ly6g5b gene are produced by transcription-induced chimerism and are conserved across six mammalian species; overexpression studies showed that CSNK2B, LY6G5B, and CSNK2B-LY6G5B chimeric proteins display different patterns of post-translational modifications and distinct subcellular distributions, and some chimeric transcripts encode CSNK2B proteins with an altered C-terminus that could affect substrate specificity. RT-PCR across six mammalian species, overexpression of tagged constructs, immunofluorescence/localization analysis BMC genomics Medium 23521802
2014 CSNK2B (as the CK2 component of the PRC1-AUTS2 complex) was found to neutralize PRC1 repressive activity, allowing AUTS2-mediated recruitment of P300 and consequent gene activation in the CNS; this places CK2β within an epigenetic activation complex rather than in its canonical repressive context. Biochemical purification of PRC1-AUTS2 complex, ChIP-seq, conditional mouse CNS knockout Nature High 25519132
2018 Knockdown of CSNK2B in neural stem cells promotes proliferation and inhibits differentiation, and alters neuronal morphology and synaptic transmission, establishing a functional role for CSNK2B in neural stem cell fate and neuronal development. shRNA knockdown in neural stem cells, proliferation and differentiation assays, neuronal morphology analysis, synaptic transmission measurement Nature communications Medium 29483533
2020 TNFAIP1 physically interacts with CSNK2B and promotes its Cul3-mediated ubiquitin-dependent degradation, thereby attenuating CSNK2B-dependent NF-κB transactivation in hepatocellular carcinoma cells; enforced CSNK2B expression counteracts TNFAIP1's tumor-suppressive effects. LC-MS/MS, Co-immunoprecipitation, Western blot, dual-luciferase reporter, rescue overexpression experiments in vitro and in vivo EBioMedicine High 31901862
2022 Disease-associated missense variants at Asp32 of CSNK2B (p.Asp32His and p.Asp32Asn) upregulate CSNK2B transcript and protein levels, impair the interaction of CK2β with DVL3 and β-catenin, reduce phosphorylation of β-catenin, abolish active β-catenin nuclear accumulation, and broadly dysregulate canonical Wnt signaling; whole-phosphoproteome analysis showed absence of phosphorylation of 313 putative CK2 substrates enriched in Wnt/β-catenin targets. Patient-derived lymphoblastoid cell lines, Co-IP, Western blot, whole-transcriptome profiling, whole-phosphoproteome mass spectrometry, immunofluorescence HGG advances High 35571680
2023 CSNK2B directly interacts with IRF1 and constitutively modulates its transcriptional activity; genome-wide CUT&RUN revealed that CSNK2B broadly enhances IRF1 binding to chromatin to upregulate antiviral genes (e.g., PLAAT4/RARRES3), while its depletion causes aberrant IRF1 accumulation at AFAP1 loci. CSNK2B also mediates phosphorylation-dependent activation of the AFAP1-Src signaling axis and exerts suppressive activity against flaviviruses including dengue virus. Proteomics interactome screen, Co-IP, genome-wide CUT&RUN, siRNA knockdown, antiviral assays Nucleic acids research High 37094077
2023 HIKER/LINC02228 lncRNA regulates erythropoiesis in Monge's disease through CSNK2B: downregulation of HIKER reduces CSNK2B expression and severely impairs erythropoiesis, while re-expression of CSNK2B on a HIKER-knockdown background rescues erythropoiesis. Pharmacological inhibition or zebrafish knockdown of CSNK2B reduces erythroid colony formation and hemoglobinization. RNA-Seq, lncRNA knockdown/overexpression, CSNK2B rescue overexpression, CK2 inhibitor assay, zebrafish morpholino knockdown The Journal of clinical investigation High 37022795
2024 RACK1 interacts with CSNK2B and inhibits its ubiquitination-mediated degradation, stabilizing CK2β; this allows CK2 to activate the NF-κB pathway, increasing CDK4 and cyclin D3 transcription and promoting G2/M cell cycle transition in meningioma cells. Protein immunoprecipitation, mass spectrometry, RNA interference, transcriptome sequencing, in vivo nude mouse experiments Cancers Medium 38398158
2021 CSNK2B promotes colorectal cancer cell proliferation primarily by activating the mTOR signaling pathway, as demonstrated by rescue experiments with mTOR pathway components. Western blot, rescue overexpression experiments, in vitro and in vivo cell viability assays Journal of cell communication and signaling Medium 33928514
2023 miR-1205 directly targets the CSNK2B 3′ UTR to suppress its expression; CSNK2B in turn promotes HCC cell proliferation through a CDK4/pRb cell cycle pathway, placing CSNK2B upstream of CDK4 in this axis. Dual-luciferase reporter assay, western blot, rescue overexpression/knockdown in vitro and in vivo Technology in cancer research & treatment Medium 36617978
2025 Pathogenic missense variants in the zinc-finger domain of CSNK2B (p.Arg111Pro, p.Cys137Phe) reduce CK2β protein stability through proteasomal and lysosomal degradation and significantly impair CK2β homodimerization, while not affecting CK2α binding; other variants (p.Asp32Asn, p.Arg86Cys) do not affect stability or CK2β/α binding, suggesting variant-class-specific mechanisms. Zinc-finger variants also alter subcellular localization of CK2β. Western blot, proteasome/lysosome inhibitor assays, co-immunoprecipitation for homodimerization and CK2α binding, immunofluorescence localization Biological chemistry Medium 40317201
2023 Haploinsufficiency of CSNK2B (loss-of-function mutations leading to reduced CK2β protein via mRNA and protein instability) results in reduced overall CK2 holoenzyme complex formation and reduced kinase activity, identified as the primary pathomechanism of Poirier-Bienvenu syndrome; patient-derived cells with p.Leu39Arg and p.Met132LeufsTer110 variants show mutant mRNA/protein instability. In vitro functional assays, western blot, mRNA stability analysis in patient-derived cells, structural and predictive analysis Genes Medium 36833176
2025 AAV-PHP.eB-mediated brain-wide CSNK2B gene replacement in Csnk2b haploinsufficient mice restored cortical and hippocampal structure, normalized neuronal numbers and PV-interneuron density, prolonged survival, and ameliorated spontaneous seizures and ASD-like social/cognitive behaviors; EEG signatures (theta/gamma power and inter-areal coherence) were also corrected, indicating re-establishment of excitation/inhibition balance. Csnk2b+/– mouse model, neonatal retro-orbital AAV injection, behavioral assays, histology, EEG recording bioRxivpreprint Medium bio_10.1101_2025.10.23.684260

Source papers

Stage 0 corpus · 66 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2020 A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 3411 32353859
2006 Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2861 17081983
2012 Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell 1718 22658674
2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceedings of the National Academy of Sciences of the United States of America 1479 12477932
2009 Defining the human deubiquitinating enzyme interaction landscape. Cell 1282 19615732
2015 The BioPlex Network: A Systematic Exploration of the Human Interactome. Cell 1118 26186194
2017 Architecture of the human interactome defines protein communities and disease networks. Nature 1085 28514442
2015 A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell 1015 26496610
2020 A reference map of the human binary protein interactome. Nature 849 32296183
2007 Large-scale mapping of human protein-protein interactions by mass spectrometry. Molecular systems biology 733 17353931
2021 Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 705 33961781
2012 PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Molecular cell 698 22325352
2012 A census of human soluble protein complexes. Cell 689 22939629
2011 Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Briefings in bioinformatics 656 21873635
2006 A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 610 16713569
2020 Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science (New York, N.Y.) 564 33060197
2004 The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome research 438 15489334
2022 OpenCell: Endogenous tagging for the cartography of human cellular organization. Science (New York, N.Y.) 432 35271311
2015 Panorama of ancient metazoan macromolecular complexes. Nature 407 26344197
2011 Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. The New England journal of medicine 394 21323541
2004 14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. The Biochemical journal 372 14744259
2007 Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme. Molecular cell 367 17643375
2001 Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. The EMBO journal 357 11574463
2021 A proximity-dependent biotinylation map of a human cell. Nature 339 34079125
2001 Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Molecular cell 294 11583622
1994 The phosphorylation of the respiratory burst oxidase component p47phox during neutrophil activation. Phosphorylation of sites recognized by protein kinase C and by proline-directed kinases. The Journal of biological chemistry 277 8089108
2012 A high-throughput approach for measuring temporal changes in the interactome. Nature methods 273 22863883
2011 A directed protein interaction network for investigating intracellular signal transduction. Science signaling 258 21900206
2014 An AUTS2-Polycomb complex activates gene expression in the CNS. Nature 255 25519132
2001 A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Molecular cell 253 11239457
2018 Comprehensive integrative analyses identify GLT8D1 and CSNK2B as schizophrenia risk genes. Nature communications 86 29483533
1995 Cloning and disruption of CKB1, the gene encoding the 38-kDa beta subunit of Saccharomyces cerevisiae casein kinase II (CKII). Deletion of CKII regulatory subunits elicits a salt-sensitive phenotype. The Journal of biological chemistry 79 7737972
2019 Identification of de novo CSNK2A1 and CSNK2B variants in cases of global developmental delay with seizures. Journal of human genetics 64 30655572
2017 CSNK2B splice site mutations in patients cause intellectual disability with or without myoclonic epilepsy. Human mutation 56 28585349
1994 Cloning and disruption of CKB2, the gene encoding the 32-kDa regulatory beta'-subunit of Saccharomyces cerevisiae casein kinase II. The Journal of biological chemistry 45 8027080
2020 Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma. EBioMedicine 36 31901862
2019 Germline de novo variants in CSNK2B in Chinese patients with epilepsy. Scientific reports 31 31784560
2019 Huaier Suppresses Breast Cancer Progression via linc00339/miR-4656/CSNK2B Signaling Pathway. Frontiers in oncology 30 31781497
1996 Localization of eight additional genes in the human major histocompatibility complex, including the gene encoding the casein kinase II beta subunit (CSNK2B). Genomics 26 8812450
2021 CSNK2B: A broad spectrum of neurodevelopmental disability and epilepsy severity. Epilepsia 25 34041744
2022 De novo variants of CSNK2B cause a new intellectual disability-craniodigital syndrome by disrupting the canonical Wnt signaling pathway. HGG advances 21 35571680
2021 Overexpression of NELFE contributes to gastric cancer progression via Wnt/β-catenin signaling-mediated activation of CSNK2B expression. Journal of experimental & clinical cancer research : CR 19 33526068
2020 Poirier-Bienvenu neurodevelopmental syndrome: A report of a patient with a pathogenic variant in CSNK2B with abnormal linear growth. American journal of medical genetics. Part A 17 33166063
2021 CSNK2B contributes to colorectal cancer cell proliferation by activating the mTOR signaling. Journal of cell communication and signaling 15 33928514
2022 Predictive functional, statistical and structural analysis of CSNK2A1 and CSNK2B variants linked to neurodevelopmental diseases. Frontiers in molecular biosciences 14 36310603
2021 Clinical and genetic analysis of six Chinese children with Poirier-Bienvenu neurodevelopmental syndrome caused by CSNK2B mutation. Neurogenetics 14 34370157
2017 CKB1 is involved in abscisic acid and gibberellic acid signaling to regulate stress responses in Arabidopsis thaliana. Journal of plant research 12 28342111
2023 Long noncoding RNA HIKER regulates erythropoiesis in Monge's disease via CSNK2B. The Journal of clinical investigation 10 37022795
2022 Two different presentations of de novo variants of CSNK2B: two case reports. Journal of medical case reports 10 34983633
2022 De Novo CSNK2B Mutations in Five Cases of Poirier-Bienvenu Neurodevelopmental Syndrome. Frontiers in neurology 9 35370893
2019 CKB1 regulates expression of ribosomal protein L10 family gene and plays a role in UV-B response. Plant biology (Stuttgart, Germany) 9 30597713
2022 Splicing Interruption by Intron Variants in CSNK2B Causes Poirier-Bienvenu Neurodevelopmental Syndrome: A Focus on Genotype-Phenotype Correlations. Frontiers in neuroscience 7 35774559
2013 Intron retention and transcript chimerism conserved across mammals: Ly6g5b and Csnk2b-Ly6g5b as examples. BMC genomics 7 23521802
2023 Haploinsufficiency as a Foreground Pathomechanism of Poirer-Bienvenu Syndrome and Novel Insights Underlying the Phenotypic Continuum of CSNK2B-Associated Disorders. Genes 6 36833176
2024 RACK1 Promotes Meningioma Progression by Activation of NF-κB Pathway via Preventing CSNK2B from Ubiquitination Degradation. Cancers 5 38398158
2023 CSNK2B modulates IRF1 binding to functional DNA elements and promotes basal and agonist-induced antiviral signaling. Nucleic acids research 5 37094077
2023 Genetic analysis and literature review of a Poirier-Bienvenu neurodevelopmental syndrome family line caused by a de novo frameshift variant in CSNK2B. Molecular genetics & genomic medicine 4 38037515
2024 Case report: Novel deletions in the 6p21.33 involving the CSNK2B gene in patients with Poirier-Bienvenu neurodevelopmental syndrome and literature review. Frontiers in medicine 2 39493709
2024 Curzerenone inactivates the nuclear factor-kappa B signaling to suppress malignancy and immune evasion in cervical cancer by targeting CSNK2B. Human cell 2 39718697
2023 MicroRNA-1205 Suppresses Hepatocellular Carcinoma Cell Proliferation via a CSNK2B/CDK4 Axis. Technology in cancer research & treatment 2 36617978
2023 Refining of the electroclinical phenotype in familial and sporadic cases of CSNK2B-related Neurodevelopmental Syndrome. Epilepsy & behavior : E&B 2 37717460
2022 [De novo variant of CSNK2B causes Poirier-Bienvenu neurodevelopmental syndrome: two case report]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 1 35598262
2026 Dravet Syndrome Associated With a CSNK2B-Related Neurodevelopmental Disorder. Cureus 0 41890472
2025 Genetic analysis of four cases of Poirier Bienvenu neurodevelopmental syndrome associated with CSNK2B variant. BMC medical genomics 0 40211296
2025 Pathogenic missense variants of CSNK2B associated with Poirier-Bienvenu neurodevelopmental disorder impact differently on CK2 holoenzyme formation. Biological chemistry 0 40317201
2024 CSNK2B Mutation: A Rare Cause of IGHD. Clinical endocrinology 0 39676320